Trial Condition(s):

Hypertension

Study on safety, tolerability and pharmacokinetics of one tablet Adalat OROS 30 or of one tablet Nifedipine Sandoz retard 30 after an overnight fasting or immediately after an American breakfast in healthy male volunteers

Bayer Identifier:

11819

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2004-004125-10

Study Completed

Trial Purpose

Please see attached Study Results Summary below

Inclusion Criteria

No Inclusion Criteria Available

Exclusion Criteria

No Exclusion Criteria Available

Trial Summary

Enrollment Goal

Trial Dates

January2005

February2005

Phase

Could I receive a placebo?

Products

Adalat Oros (Nifedipine, BAYA1040)

Accepts Healthy Volunteers

N/A

Where to Participate

Locations

Status

Locations	Status
Locations SocraTec R&D Clinical Ward Erfurt, Germany, 99084	Status Completed		Contact Us: E-mail: [email protected] Phone: Not Available

Locations

Status

Locations

SocraTec R&D Clinical Ward

Erfurt, Germany, 99084

Status

Completed

Contact Us:

E-mail: [email protected]

Phone: Not Available

Hypertension

Bayer Identifier:

ClinicalTrials.gov Identifier:

EudraCT Number:

Trial Purpose

Key Participation Requirements

sex

age

18 Years

40 Years

Inclusion Criteria

Exclusion Criteria

Inclusion Criteria

Exclusion Criteria

Trial Summary

Enrollment Goal

Trial Dates

Phase

Could I receive a placebo?

Products

Accepts Healthy Volunteers

Where to Participate

For details, please refer to trial results

Additional Information